Edition:
United States

Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

3.14USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$3.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
223,995
52-wk High
$5.71
52-wk Low
$1.08

Latest Key Developments (Source: Significant Developments)

Verastem Announces Pricing Of Public Offering Of Common Stock
Friday, 15 Dec 2017 09:18am EST 

Verastem Inc ::VERASTEM ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - ANNOUNCED PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF APPROXIMATELY $25 MILLION OF SHARES OF ITS COMMON STOCK.  Full Article

Verastem Announces Public Offering Of Common Stock
Thursday, 14 Dec 2017 05:07pm EST 

Dec 14 (Reuters) - Verastem Inc ::VERASTEM ANNOUNCES PUBLIC OFFERING OF COMMON STOCK.VERASTEM INC - INTENDS TO OFFER AND SELL $25 MILLION OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​
Sunday, 10 Dec 2017 04:30pm EST 

Dec 10 (Reuters) - Verastem Inc ::‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​.‍DUO STUDY ACHIEVES PRIMARY ENDPOINT, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS FOR DUVELISIB VERSUS OFATUMUMAB​.‍PLANS TO SUBMIT A NDA TO U.S. FDA REQUESTING FULL APPROVAL OF DUVELISIB​.‍PLANS TO SUBMIT ACCELERATED APPROVAL OF DUVELISIB FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY FL ​.‍EXPECTS TO SUBMIT DUVELISIB NDA DURING Q1 OF 2018​.  Full Article

Verastem reports Q3 loss per share of $0.61
Tuesday, 7 Nov 2017 07:00am EST 

Nov 7 (Reuters) - Verastem Inc :Verastem reports third quarter 2017 financial results.Q3 loss per share $0.61.Q3 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Verastem - based on current plans,​ ‍expect to have sufficient cash, cash equivalents & investments to fund research and development programs & operations into H2 2018.  Full Article

Verastem says ‍plans to submit NDA for duvelisib during Q1 of 2018​
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Verastem Inc -:Verastem announces regulatory strategy for duvelisib, new drug application following guidance from FDA.Verastem Inc - ‍plans to submit NDA for duvelisib during Q1 of 2018​.  Full Article

Verastem expands duvelisib development program to include peripheral T-cell lymphoma
Wednesday, 6 Sep 2017 06:05am EDT 

Sept 6 (Reuters) - Verastem Inc -:Verastem expands duvelisib development program to include peripheral T-cell lymphoma.Verastem Inc - ‍duvelisib receives fast track designation from FDA in PTCL; company to initiate a phase 2 clinical trial by year end 2017​.Verastem Inc - verastem expects that phase 2 study of duvelisib will be conducted in both U.S. and Japan.  Full Article

Verastem announces positive top-line data from the pivotal phase 3 Duo study
Wednesday, 6 Sep 2017 06:01am EDT 

Sept 6 (Reuters) - Verastem Inc :Verastem announces positive top-line data from the pivotal phase 3 Duo study in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.‍Plans to share clinical data from pivotal phase 3 Duo study​ with FDA with goal of filing new drug application during first half of 2018.  Full Article

Verastem Inc enters into an amendment to its sales agreement
Monday, 28 Aug 2017 06:05pm EDT 

Aug 28 (Reuters) - Verastem Inc ::Verastem Inc says entered into an amendment to its sales agreement, dated March 30 with Cantor Fitzgerald.Verastem Inc says under amendment, co increased offering price of shares of common stock that it may issue and sell to $75 million from $35 million .  Full Article

Verastem Q2 loss per share $0.36
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Verastem Inc :Verastem reports second quarter 2017 financial results.Q2 loss per share $0.36.Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S.Verastem Inc says expects to report top-line data from DUO study in latter part of summer 2017.  Full Article

Ridgeback Capital Investments reports 7.7 pct passive stake in Verastem
Thursday, 20 Jul 2017 04:50pm EDT 

July 20 (Reuters) - Verastem Inc :Ridgeback Capital Investments Lp reports a 7.7 percent passive stake in Verastem inc as of July 10, 2017 - sec filing.  Full Article